ADHD drugs should carry warning, FDA committee recommendsBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7544.748-c (Published 30 March 2006) Cite this as: BMJ 2006;332:748
- Janice Tanne
- New York
An advisory committee to the US Food and Drug Administration has voted to recommend that black box warnings—the most serious—be put on drugs prescribed for attention deficit hyperactivity disorder (ADHD) because of concerns over cardiovascular effects. Another committee recommended warning doctors and patients that these drugs could cause hallucinations. Both committees recommended information leaflets for patients.
The FDA can accept or reject committee recommendations. A spokesperson for the agency told the BMJ that no decision had yet been made. Details of why the drug safety and risk management advisory committee voted in …
Log in using your username and password
Log in through your institution
Sign up for a free trial